RKS262
RKS262 is an orally active cyclin/CDK inhibitor. RKS262 is also an apoptosis inducer and cell cycle regulator, exhibiting cytotoxic activity against cancer cells. RKS262 induces caspase-3 cleavage, ROS generation, SAPK/JNK activation, and upregulates the expression of p53, Bid, Bad, Bok, and p27. RKS262 inhibits the expression of Bcl-2, Mcl-1, Bcl-xL, p21, cyclin D1, cyclin B1, cdc-2, cyclin D4, and DNA-pk KU-80 subunit. RKS262 suppresses the phosphorylation of the IGF-1R/PI3K/PKC pathway, ras oncogene activity, and Cdk-6, while increasing total Akt expression. RKS262 induces G2/M or S phase cell cycle arrest, disrupts mitochondrial transmembrane potential, and reduces tumor burden in xenograft models. RKS262 is used in research on neuroblastoma and ovarian cancer.
For research use only. We do not sell to patients.
- CAS No.: 1041469-97-9
- Formula: C15H14BrClN2O4S
- Molecular Weight:433.70
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BE(2)-C | IC50 |
10.23 μM
|
Antiproliferative activity against human Be(2)C neuroblastoma cells assessed as reduction in cell viability incubated for 48 hrs by Calcein AM assay.
Antiproliferative activity against human Be(2)C neuroblastoma cells assessed as reduction in cell viability incubated for 48 hrs by Calcein AM assay.
|
21532338 |
| SH-SY5Y | IC50 |
7.12 μM
|
Antiproliferative activity against human SHSY5Y neuroblastoma cells assessed as reduction in cell viability incubated for 48 hrs by Calcein AM assay.
Antiproliferative activity against human SHSY5Y neuroblastoma cells assessed as reduction in cell viability incubated for 48 hrs by Calcein AM assay.
|
21532338 |
| OVCAR-3 | IC50 |
3 μM
|
Cytotoxicity against human ovarian epithelial adenocarcinoma OVCAR-3 cells assessed via cell-cycle analysis by flow cytometry after 24 h treatment.
Cytotoxicity against human ovarian epithelial adenocarcinoma OVCAR-3 cells assessed via cell-cycle analysis by flow cytometry after 24 h treatment.
|
19865799 |
In Vitro
RKS262 (0-50 μM; 48 h) potently inhibits the growth of Be (2) C, CHLA-90, LA1-55n, LAN-2, SMSKCNR, and SHSY5Y neuroblastoma cell lines in vitro, with IC50 values ranging from 6.97 μM to 24.3 μM[1].
RKS262 (10 nM-100 μM) potently inhibits the growth of most NCI-60 human cancer cell lines, with leukemia cell lines being the most sensitive (GI50 of 10 nM), whereas some non-small cell lung, breast, central nervous system, melanoma, renal, and ovarian cancer cell lines are relatively resistant (GI50 >1 μM); in a panel of ovarian cancer cell lines treated at 100 nM or 100 μM, this compound exhibits dose-dependent growth inhibition[2].
RKS262 (5 μM; 48 h) exhibits high cytotoxicity against human ovarian cancer cells OVCAR-3[2].
RKS262 (5 μM; 1-36 h) modulates key oncogenic and signaling pathways in human ovarian cancer cells OVCAR-3: it inhibits ras within 1 h, downregulates DNA-pk KU-80 in a time-dependent manner (starting at 6 h and reaching background levels by 18 h), and, during 36 h of treatment at 5 μM, first induces Akt phosphorylation and activation, followed by its downregulation (with a concurrent increase in total Akt expression)[2].
RKS262 (11 μM; 15 h) induces DNA fragmentation and apoptotic/necrotic cell death in SMSKCNR neuroblastoma cells[1].
RKS262 (7 μM; 4-24 h) activates SAPK/JNK and caspase-3, cleaves PARP-1, and inhibits IGF-1R/PI3K/PKC phosphorylation in SMSKCNR neuroblastoma cells; pretreatment with 100 μM ascorbic acid or 20 μM SB203580 (HY-10256) reverses these effects[1].
RKS262 (7 μM; 4-24 h) inhibits anti-apoptotic Bcl-2 family proteins (Mcl-1, Bcl-xL, phosphorylated Bcl-2) in SMSKCNR neuroblastoma cells, and pretreatment with 20 μM SB203580 reverses its inhibitory effect on phosphorylated Bcl-2[1].
RKS262 (11.5-50 μM; 30 min) induces dose-dependent ROS generation in LA1-55n, SMSKCNR, and SHSY5Y neuroblastoma cells[1].
RKS262 (23 μM; 24 h) exhibits reduced cytotoxicity in SMSKCNR neuroblastoma cells pretreated with 10 mM N-Acetylcysteine amide (NAC) (HY-110256) for 3 h[1].
RKS262 (7 μM; 24 h) induces G2/M phase arrest and downregulates the expression of cdc2, cyclin B1, p21, cyclin D1, and cyclin D4, while upregulating p53 expression; pretreatment with 100 μM ascorbic acid or 20 μM SB203580 partially reverses these effects[1].
RKS262 (5-7 μM; 4-24 h) reverses the activation state of SAPK/JNK or ROS in SMSKCNR neuroblastoma cells pretreated with exogenous BDNF; when treated with 7 μM RKS262 for 24 h, co-treatment with BDNF, EGF, or IGF-1 shifts RKS262-induced cell cycle arrest from the G2/M phase to the S phase[1].
RKS262 (5 μM; 12 h) disrupts the mitochondrial membrane potential in human ovarian cancer OVCAR-3 cells, leading to the loss of ΔYm[2].
RKS262 (1-3 μM; 24 h) arrests the cell cycle progression of human ovarian cancer OVCAR-3 cells at the G2/M phase[2].
RKS262 (5 μM; 24 h) regulates the expression of cell cycle regulatory proteins in human ovarian cancer OVCAR-3 cells, upregulating p27 expression and downregulating cyclin D1 and CDK-6 expression, without altering the levels of p21 or p16[2].
RKS262 (5 μM; 1-18 h) induces apoptosis in human ovarian cancer OVCAR-3 cells, activates caspase-3 and caspase-7, and cleaves PARP-1[2].
RKS262 (5 μM; 1-36 h) selectively modulates the expression of Bcl2 family proteins in human ovarian cancer OVCAR-3 cells: it activates pro-apoptotic proteins Bid and Bad within 1 h, upregulates pro-apoptotic protein Bok at 36 h, downregulates anti-apoptotic proteins Bcl-xl and Mcl-1 within 6 h under 5 μM treatment, and does not alter the expression levels of Bax or Bak[2].
RKS262 (3 μM) induces apoptosis by regulating Bcl-2 family proteins and mitochondrial depolarization, exhibiting strong cytotoxicity in human ovarian cancer OVCAR-3 cells, with its activity correlated with RAS oncogene status[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Be(2)C, CHLA-90, LA1-55n, LAN-2, SMSKCNR, SHSY5Y human neuroblastoma cell lines
-
Concentration:0, 11.5, 23, 50 μM
-
Incubation Time:48 h
-
Result:Inhibited cell growth in a concentration-dependent manner across all six cell lines.
Reduced surviving cells to 5-10% in all cell lines at 23 or 50 μM.
Achieved IC50 values of 10.23 μM (Be(2)C), 21.47 μM (CHLA-90), 24.3 μM (LA1-55n), 6.97 μM (LAN-2), 7.32 μM (SMSKCNR), and 7.12 μM (SHSY5Y).
-
Cell Line:SMSKCNR human neuroblastoma cells
-
Concentration:11 μM
-
Incubation Time:15 h
-
Result:Induced a significant number of TUNEL-positive nuclei compared to vehicle controls.
-
Cell Line:SMSKCNR human neuroblastoma cells
-
Concentration:7 μM (RKS262); 100 μM (ascorbic acid pre-treatment); 20 μM (SB203580 pre-treatment)
-
Incubation Time:4-24 h (RKS262); 1 h (ascorbic acid/SB203580 pre-treatment)
-
Result:Caused strong, sustained activation of phosphorylated SAPK/JNK between 4 and 12h, but not at 24h.
Induced time-dependent cleavage of caspase-3 increasing over 4, 12, 24h.
Induced PARP-1 cleavage at 12 and 24h.
Suppressed phosphorylation of IGF-1R, PI3K, and PKC between 12 and 24h.
Suppressed phosphorylated SAPK/JNK and reduced cleaved caspase-3 levels at 24h with pre-treatment of ascorbic acid or SB203580.
Reversed suppression of IGF-1R/PI3K/PKC phosphorylation with pre-treatment of ascorbic acid or SB203580.\nSuppressed expression of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-xL, and phospho-Bcl-2.
Left pro-apoptotic Bax and Bid levels unchanged.
Reversed RKS262-induced suppression of phospho-Bcl-2 with pre-treatment of SB203580, but not ascorbic acid.
-
Cell Line:SMSKCNR human neuroblastoma cells
-
Concentration:7 μM (RKS262); 100 μM (ascorbic acid pre-treatment); 20 μM (SB203580 pre-treatment)
-
Incubation Time:24 h (RKS262); 1 h (ascorbic acid/SB203580 pre-treatment)
-
Result:Increased the G2/M-phase cell population to ~50% and reduced the G1-phase population compared to vehicle controls, with S-phase population largely unchanged.
Induced time-dependent downregulation of cdc2, cyclin B1, p21, cyclin D1, and cyclin D4, and upregulation of p53 between 4 and 24h.
Reversed suppression of cdc2, cyclin B1, and cyclin D4 with pre-treatment of ascorbic acid or SB203580.
Halted p53 activation with pre-treatment of ascorbic acid.
-
Cell Line:human ovarian epithelial adenocarcinoma OVCAR-3 cells
-
Concentration:1 μM, 3 μM
-
Incubation Time:24 h
-
Result:Caused significant increase in G2/M-phase cell population and reduction in G1-phase cell population compared to untreated controls.
Induced a G2/M-phase cell-cycle block within 24 h of treatment.
-
Cell Line:human ovarian epithelial adenocarcinoma OVCAR-3 cells
-
Concentration:5 μM
-
Incubation Time:1 h, 18 h
-
Result:Activated/cleaved executioner caspase-3 and caspase-7 within 1 h, with maximal activation at 18 h.
Induced cleavage of PARP-1 within 1 h of treatment, a marker of apoptotic cell disassembly.\nCaused only minor upregulation/activation of SAP/JNK and p38 MAPK.
Indicated induced cytotoxicity is mainly independent of these proapoptotic MAPKs.
-
Cell Line:human ovarian epithelial adenocarcinoma OVCAR-3 cells
-
Concentration:5 μM
-
Incubation Time:1 h, 6 h, 18 h, 36 h
-
Result:Exerted strong inhibitory effects on oncogene ras within 1 h of treatment.
Initially upregulated DNA-pk KU-80 subunit expression, then down-regulated KU-80 to background levels by 18 h, with down-regulation beginning at 6 h.
Activated Akt within 1 h, then down-regulated Akt phosphorylation to background levels by 36 h, with cells counteracting this by increasing Akt expression over time.
-
Cell Line:human ovarian epithelial adenocarcinoma OVCAR-3 cells
-
Concentration:5 μM
-
Incubation Time:1 h, 6 h, 36 h
-
Result:Caused strong, rapid (within 1 h), and sustained (up to 36 h) activation of pro-apoptotic Bid and Bad.
Up-regulated pro-apoptotic Bok after 36 h.
Left levels of pro-apoptotic Bax and Bak unchanged.
Strongly down-regulated expression of anti-apoptotic Bcl-xl and Mcl-1 within 6 h of treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Crl:NU-Foxn1^nu (female, 6 weeks old, subcutaneous xenograft via flank injection of 1 × 107 SMSKCNR cells suspended in Matrigel)[1]
-
Dosage:150 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Reduced average tumor volume from 2.35 cm3 to 0.967 cm3, representing a 60% reduction in tumor burden.
Showed no ulcer formation at the tumor site, secondary pathological conditions, changes in behavior, average weight, or toxicity.
Chemical Information
-
CAS No. 1041469-97-9
-
Molecular Weight 433.70
-
Formula C15H14BrClN2O4S
-
SMILES
O=C1OC2=C(C(Cl)=C1/C=N/N3CCS(=O)(CC3C)=O)C=C(Br)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)